相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
H. Pfeifer et al.
LEUKEMIA (2019)
How I treat Philadelphia chromosome- positive acute lymphoblastic leukemia
Farhad Ravandi
BLOOD (2019)
Minimal Residual Disease-Based Long-Term Efficacy of Reduced-Intensity Conditioning Versus Myeloablative Conditioning for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia
Jae-Ho Yoon et al.
CANCER (2019)
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
Konstantin Byrgazov et al.
HAEMATOLOGICA (2018)
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study
Naoto Takahashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
Konstantin Byrgazov et al.
HAEMATOLOGICA (2018)
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Jing Wang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia
Stuart L. Goldberg et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
Masaya Okada et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Pierre Laneuville
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT
Sebastian Giebel et al.
EUROPEAN JOURNAL OF CANCER (2018)
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
Naoto Takahashi et al.
HAEMATOLOGICA (2018)
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
David M. Ross et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele et al.
LANCET ONCOLOGY (2018)
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Simona Soverini et al.
MOLECULAR CANCER (2018)
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia
Massimo Breccia et al.
CURRENT ONCOLOGY REPORTS (2018)
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
Naoto Takahashi et al.
HAEMATOLOGICA (2018)
New Approaches to the Management of Adult Acute Lymphoblastic Leukemia
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour et al.
LANCET HAEMATOLOGY (2018)
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Delphine Rea et al.
BLOOD (2017)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A. Hochhaus et al.
LEUKEMIA (2017)
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
Mohamed El Missiry et al.
PLOS ONE (2017)
The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults
M. R. Litzow et al.
BONE MARROW TRANSPLANTATION (2017)
Prognostic Factors and Survival Outcomes in Patients With Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients
Preetesh Jain et al.
CANCER (2017)
Overall Survival With Ponatinib Versus Allogeneic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemias With the T315I Mutation
Franck E. Nicolini et al.
CANCER (2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2017)
Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph plus ALL: a study from the adult ALL WG of the JSHCT
S. Nishiwaki et al.
BONE MARROW TRANSPLANTATION (2016)
Management of CML-blast crisis
Ruediger Hehlmann et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2016)
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome
Federico Lussana et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Nicholas J. Short et al.
BLOOD (2016)
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL
Philippe Rousselot et al.
BLOOD (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sebastian Gebel et al.
CANCER (2016)
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
Sabina Chiaretti et al.
HAEMATOLOGICA (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The concept of treatment-free remission in chronic myeloid leukemia
S. Saussele et al.
LEUKEMIA (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
Konstantin Byrgazov et al.
ONCOTARGET (2016)
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
Sabina Chiaretti et al.
HAEMATOLOGICA (2016)
US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL
Farhad Ravandi et al.
BLOOD ADVANCES (2016)
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
Sung-Nam Lim et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group
Noriyoshi Iriyama et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
Silvia Mori et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia
Dae-Young Kim et al.
BLOOD (2015)
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
Yves Chalandon et al.
BLOOD (2015)
Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing
Lucia Cavelier et al.
BMC CANCER (2015)
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Farhad Ravandi et al.
CANCER (2015)
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Naval Daver et al.
HAEMATOLOGICA (2015)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2015)
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Naval Daver et al.
HAEMATOLOGICA (2015)
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
Henrik Hjorth-Hansen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Timothy P. Hughes et al.
BLOOD (2014)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour et al.
BLOOD (2014)
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
Adele K. Fielding et al.
BLOOD (2014)
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Susan Branford et al.
BLOOD (2014)
Drug Resistance and BCR-ABL Kinase Domain Mutations in Philadelphia Chromosome- Positive Acute Lymphoblastic Leukemia From the Imatinib to the Second- Generation Tyrosine Kinase Inhibitor Era
Simona Soverini et al.
CANCER (2014)
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Matthew S. Zabriskie et al.
CANCER CELL (2014)
Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing
R. Kastner et al.
EUROPEAN JOURNAL OF CANCER (2014)
Current and future management of Ph/BCR-ABL positive ALL
Elena Maino et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy
Gabriel Etienne et al.
HAEMATOLOGICA (2014)
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ph plus ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
V. Bachanova et al.
LEUKEMIA (2014)
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
B. Hanfstein et al.
LEUKEMIA (2014)
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
Simona Soverini et al.
LEUKEMIA RESEARCH (2014)
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib
Sung-Eun Lee et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Preetesh Jain et al.
BLOOD (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
Simona Soverini et al.
BLOOD (2013)
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia
H. Pfeifer et al.
LEUKEMIA (2013)
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
David Marin et al.
BLOOD (2012)
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol
Santhosh Thyagu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation
Josep-Maria Ribera et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
S. Lee et al.
LEUKEMIA (2012)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
B. Hanfstein et al.
LEUKEMIA (2012)
Standardized definitions of molecular response in chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2012)
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis
Simona Soverini et al.
PHARMACOGENOMICS (2012)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Robin Foa et al.
BLOOD (2011)
Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy
Wendy T. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparative In Vitro Cellular Data Alone Are Insufficient to Predict Clinical Responses and Guide the Choice of BCR-ABL Inhibitor for Treating Imatinib-Resistant Chronic Myeloid Leukemia
Pierre Laneuville et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Sara Redaelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL)
Oliver G. Ottmann et al.
CANCER (2007)
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy:: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol
Marco Vignetti et al.
BLOOD (2007)
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia:: results of the GRAAPH-2003 study
Adrienne de Labarthe et al.
BLOOD (2007)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Barbara Wassmann et al.
BLOOD (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia:: A phase II study by the Japan Adult Leukemia Study Group
M Yanada et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
B Wassmann et al.
BLOOD (2005)
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia
F Pane et al.
LEUKEMIA (2005)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia:: a study from the Acute Leukemia French Association (ALFA)
C Preudhomme et al.
BLOOD (2002)
Combination therapy with imatinib mesylate (STI571):: Synopsis of in vitro studies
J Topaly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
分享论文
